Robust Performance in Q1 and Positive Projections
Strong start to the year and confirmed full-year outlook
Ester Baiget, President & CEO, shared her enthusiasm regarding the company's impressive sales growth in the first quarter. She stated, “We delivered strong sales growth and earnings in the first quarter, with all four sales areas showing double-digit growth. Our growth was driven by fresh innovations, particularly in emerging markets, alongside a sustained demand for our solutions in developed regions. The anticipated synergies are materializing, and we are confident in our full-year outlook. Our resilient global structure and regional presence empower us to respond effectively to market dynamics.”
Key Financial Highlights
The results from the first quarter of 2025 illustrated significant achievements:
- Organic sales grew substantially by 11%, which included approximately 1 percentage point attributed to pricing strategies. Each sales market experienced double-digit growth, with emerging markets achieving an impressive 15% and developed markets at 9%.
- The adjusted EBITDA margin improved notably to 38.3%, an increase of 310 basis points.
- Adjusted net profit saw a remarkable increase of 27% from the previous year.
- The net interest-bearing debt to EBITDA ratio stands at 1.1x, showcasing financial health.
- On February 11, the announcement was made regarding the acquisition of dsm-firmenich’s share in the feed enzyme alliance, with an expected cash consideration of EUR 1.5 billion. This acquisition is anticipated to conclude in the second quarter.
- Leadership changes were also highlighted, announcing Andrew Taylor as the new EVP of Food & Beverages, who is expected to join the company by September 1, 2025.
- The outlook for 2025 remains robust, with projected organic sales growth between 5-8%. Excluding certain country exits, growth might range from 6-9%. Additionally, the adjusted EBITDA margin is forecasted to remain between 37-38% despite facing some currency headwinds.
Conclusion and Future Outlook
As we look ahead, the steadfast performance in the first quarter positions the company favorably for the remainder of the year. The combination of strategic acquisitions, effective market response, and anticipated leadership contributions offers a promising outlook. Stakeholders can remain optimistic as the company continues to innovate and adapt in a dynamic environment.
Frequently Asked Questions
What financial results did NSIS B report for Q1?
NSIS B reported an 11% organic sales growth, with a notable increase of 27% in adjusted net profit, along with an improved EBITDA margin of 38.3%.
What strategic acquisition is NSIS B planning?
The company announced plans to acquire dsm-firmenich’s part of the feed enzyme alliance for EUR 1.5 billion, expected to finalize in the second quarter.
How is leadership changing within NSIS B?
Andrew Taylor has been announced as the new EVP of Food & Beverages, with a joining timeline no later than September 1, 2025.
What is the growth outlook for NSIS B for 2025?
The company maintains an outlook of 5-8% organic sales growth for 2025, with an adjusted EBITDA margin aimed to stay between 37-38% amid currency challenges.
How did the pandemic affect NSIS B’s business in emerging markets?
Despite the pandemic, NSIS B has shown a robust performance with a 15% organic sales growth in emerging markets, reflecting strong demand for their innovative solutions.
